Literature DB >> 8603698

Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.

Y Maru1, O N Witte, M Shibuya.   

Abstract

Biological activities of BCR-ABL, an activated tyrosine kinase oncogene responsible for pathogenesis of human leukemias, can be completely inactivated by a deletion of the BCR aminoterminal sequence with tetramerizing property (BCR-ABL delta 1-40). We attempted several ways to restore the ability to induce growth factor independence to the de-oligomerized BCR-ABL delta 1-40 and found that an additional deletion of the ABL SH3 domain could. In BCR-ABL delta 1-40 reactivated by the SH3 deletion, transphosphoryation of other cellular proteins like p62 or SHC in vivo and autophosphorylation with recruitment of GRB-2 were also recovered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603698     DOI: 10.1016/0014-5793(95)01518-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.

Authors:  X Zhang; R Subrahmanyam; R Wong; A W Gross; R Ren
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 2.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

Review 3.  Mechanisms of transformation by the BCR/ABL oncogene.

Authors:  M Sattler; J D Griffin
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts.

Authors:  Michele Massimino; Elena Tirrò; Stefania Stella; Livia Manzella; Maria Stella Pennisi; Chiara Romano; Silvia Rita Vitale; Adriana Puma; Cristina Tomarchio; Sandra Di Gregorio; Agostino Antolino; Francesco Di Raimondo; Paolo Vigneri
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

5.  Autoinhibition of Bcr-Abl through its SH3 domain.

Authors:  Kristen M Smith; Rinat Yacobi; Richard A Van Etten
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.